Maven Securities LTD Purchases Shares of 150,000 Medicenna Therapeutics Corp. (NASDAQ:MDNA)

Maven Securities LTD acquired a new position in Medicenna Therapeutics Corp. (NASDAQ:MDNA – Get Rating) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 150,000 shares of the company’s stock, valued at approximately $124,000.

Other hedge funds have also recently made changes to their positions in the company. Toronto Dominion Bank raised its position in Medicenna Therapeutics by 1,452.2% in the second quarter. Toronto Dominion Bank now owns 29,103 shares of the company’s stock valued at $33,000 after purchasing an additional 27,228 shares during the period. Annandale Capital LLC acquired a new stake in shares of Medicenna Therapeutics in the third quarter valued at $33,000. Rathbones Group Plc raised its holdings in shares of Medicenna Therapeutics by 164.2% in the 3rd quarter. Rathbones Group Plc now owns 105,663 shares of the company’s stock valued at $87,000 after buying an additional 65,663 shares during the period. Sigma Planning Corp lifted its stake in Medicenna Therapeutics by 25.8% during the 2nd quarter. Sigma Planning Corp now owns 252,050 shares of the company’s stock worth $292,000 after acquiring an additional 51,750 shares in the last quarter. Finally, Granite Point Capital Management L.P. purchased a new position in Medicenna Therapeutics during the 3rd quarter valued at about $270,000. Hedge funds and other institutional investors own 19.68% of the company’s stock.

Medicenna Therapeutics Stock Performance

Shares of MDNA opened at $0.58 on Wednesday. The stock has a 50-day simple moving average of $0.64 and a 200-day simple moving average of $0.67. The stock has a market capitalization of $40.21 million, a PE ratio of -4.44 and a beta of 1.24. Medicenna Therapeutics Corp. has a 1 year low of $0.40 and a 1 year high of $1.88.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Guggenheim assumed coverage on Medicenna Therapeutics in a research report on Tuesday, November 29th. They issued a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $2.50 target price on shares of Medicenna Therapeutics in a research report on Wednesday, February 8th.

Medicenna Therapeutics Company Profile

(Get Rating)

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. It engages in development and commercialization of selective versions of IL-2, IL-4 and IL-13 Superkines and Empowered Cytokines for the treatment of cancers. The company was founded by Fahar Merchant and Rosemina Merchant on February 2, 2015 and is headquartered in Toronto, Canada.